Current Environment:

Summary

This is a pilot cross-sectional study of measured transcutaneous CO-oximetry in children with inflammatory and non-inflammatory conditions.

Conditions

Asthma, Allergic Rhinitis, Cystic Fibrosis, Pneumonia

Recruitment Status

Unknown status

Detailed Description

Children and young adults age 6-24 with the following conditions: asthma, pneumonia, allergic rhinitis, cystic fibrosis, and well child (without inflammatory illness) will be recruited. Subjects will be asked to complete a brief screening survey to determine if they meet inclusion criteria. Enrolled subjects will be asked to complete questionnaire forms to characterize their health, current symptoms, medications, and common exposures. Transcutaneous carboxyhemoglobin will be recorded. This study is cross-sectional and will only require one visit coinciding with the clinical visit. Analysis will determine the pairwise differences in SpCO between conditions tested.

Eligibility Criteria

Inclusion Criteria:

diagnosis of asthma, pneumonia, allergic rhinitis, or none of the previous (control group)
Ability to complete study procedures

Exclusion Criteria:

Cardiopulmonary disease outside of the specific conditions for inclusion
Prematurity
Congenital heart disease
Current diagnosis of more than one of the following: asthma, pneumonia, allergic rhinitis, cystic fibrosis, or - for controls - any current infection
Recent serious bacterial infection (except for pneumonia in the pneumonia group)
Concurrent clinical chest X-ray with findings other those that expected for the group (i.e. normal chest X-ray in pneumonia group or suspected pneumonia on chest X-ray in asthma group). To be determined by attending radiologist's interpretation.

Gender

All

Minimum Age

6 Years

Maximum Age

24 Years

Download Date

March 27, 2018

Principal Investigator

Jonathan M. Gaffin

Primary Contact Information

Jonathan M Gaffin, MD, MMSc

857-218-5379

jonathan.gaffin@childrens.harvard.edu

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team: